CIC (COVID-19-Influenza Combination)
COVID-19 & Influenza
Key Facts
About Novavax
Novavax is a mission-driven biotech focused on discovering, developing, and commercializing innovative protein-based vaccines to address serious infectious diseases. Its core achievement is the successful global commercialization of Nuvaxovid®, a COVID-19 vaccine, validating its integrated technology platform of recombinant nanoparticle antigens and the Matrix-M adjuvant. The company's strategy centers on advancing a high-value pipeline in influenza and other infectious diseases while pursuing strategic partnerships and exploring new applications for its adjuvant technology in areas like oncology to drive long-term growth.
View full company profile